Revolution Medicines, Inc. (RVMD) Tops Q1 EPS by 10c

Revolution Medicines, Inc. (NASDAQ: RVMD) reported Q1 EPS of ($0.72), $0.10 better than the analyst estimate of ($0.82). Revenue for the quarter came in at $7.01 million versus the consensus estimate of $2.5 million.

For earnings history and earnings-related data on Revolution Medicines, Inc. (RVMD) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist
• Medtronic completes $550 million Scientia Vascular acquisition